OBJECTIVES: To estimate real-life outcomes, healthcare resources use and costs in patients with post-myocardial infarction (MI), and in a subpopulation similar to the PEGASUS-TIMI 54 trial (PEG), performed to assess long-term use of ticagrelor in patients with prior MI. METHODS: Cohort study in the EGB, a 1/97 representative sample of the French nationwide claims and hospital database. Post-MI patients had MI between 2005 and 2010 and 1-year event-free period after MI (index date). PEG patients were those with at least one of these risk factors: ≥ 50 years, diabetes, history of MI, or renal disease, but without history of stroke, dialysis, and current use of oral anticoagulant. Patients were followed for 3 years after index date with censure in December 2012. The primary outcome was a composite of death, hospitalization for MI or stroke. Healthcare resources use and their costs were estimated from the societal perspective. RESULTS: